- Home
- KROS vs AMLX Comparison
KROS vs AMLX Comparison
Compare KROS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- AMLX
- Stock Information
- Founded
- KROS 2015
- AMLX 2014
- Country
- KROS United States
- AMLX United States
- Employees
- KROS N/A
- AMLX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- AMLX Health Care
- Exchange
- KROS Nasdaq
- AMLX Nasdaq
- Market Cap
- KROS 558.9M
- AMLX 459.1M
- IPO Year
- KROS 2020
- AMLX 2022
- Fundamental
- Price
- KROS $13.37
- AMLX $6.37
- Analyst Decision
- KROS Buy
- AMLX Strong Buy
- Analyst Count
- KROS 13
- AMLX 7
- Target Price
- KROS $20.63
- AMLX $11.14
- AVG Volume (30 Days)
- KROS 637.6K
- AMLX 1.8M
- Earning Date
- KROS 08-06-2025
- AMLX 08-07-2025
- Dividend Yield
- KROS N/A
- AMLX N/A
- EPS Growth
- KROS N/A
- AMLX N/A
- EPS
- KROS 0.11
- AMLX N/A
- Revenue
- KROS $214,713,000.00
- AMLX N/A
- Revenue This Year
- KROS $5,006.76
- AMLX N/A
- Revenue Next Year
- KROS N/A
- AMLX N/A
- P/E Ratio
- KROS $123.16
- AMLX N/A
- Revenue Growth
- KROS 91657.70
- AMLX N/A
- 52 Week Low
- KROS $9.12
- AMLX $1.62
- 52 Week High
- KROS $72.37
- AMLX $7.27
- Technical
- Relative Strength Index (RSI)
- KROS 42.27
- AMLX 62.68
- Support Level
- KROS $13.25
- AMLX $6.08
- Resistance Level
- KROS $13.99
- AMLX $6.59
- Average True Range (ATR)
- KROS 0.36
- AMLX 0.42
- MACD
- KROS -0.06
- AMLX 0.08
- Stochastic Oscillator
- KROS 20.75
- AMLX 77.37
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.